Head of Bayer LifeScience Center: Expect More JVs

The head of Bayer AG's new "breakthrough" R&D unit expects to form more joint ventures with cutting-edge biotechnology start-ups like the one announced with Switzerland-based CRISPR Therapeutics aimed at harnessing their technologies and linking them with Bayer's expertise.

The head of Bayer AG's new "breakthrough" R&D unit expects to form more joint ventures with cutting-edge biotechnology start-ups like the one announced with Switzerland-based CRISPR Therapeutics aimed at harnessing their technologies and linking them with Bayer's expertise.

Axel Bouchon, who heads the newly established Bayer LifeScience Center (BLSC), told Scrip the unit's purpose reflects the times.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip